Gene therapy for erectile dysfunction

What is the future?

Arnold Melman, Kelvin Davies

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Gene transfer for the treatment of erectile dysfunction has completed phase 1 safety testing and has shown the necessary safety to proceed to the next level of clinical trial. This review focuses on the background of the components of that have led to US Food and Drug Administration acceptance of human gene transfer trials for nonlethal disease.

Original languageEnglish (US)
Pages (from-to)421-426
Number of pages6
JournalCurrent Urology Reports
Volume11
Issue number6
DOIs
StatePublished - Nov 2010

Fingerprint

Erectile Dysfunction
Genetic Therapy
Safety
United States Food and Drug Administration
Genes
Clinical Trials
Therapeutics

Keywords

  • Corpora cavernous
  • Erectile dysfunction
  • Gene transfer
  • Naked DNA, Overactive bladder
  • Phase I trial
  • Plasmid
  • Smooth muscle

ASJC Scopus subject areas

  • Urology

Cite this

Gene therapy for erectile dysfunction : What is the future? / Melman, Arnold; Davies, Kelvin.

In: Current Urology Reports, Vol. 11, No. 6, 11.2010, p. 421-426.

Research output: Contribution to journalArticle

@article{262ded7c56b44013aa421df29ba70fb8,
title = "Gene therapy for erectile dysfunction: What is the future?",
abstract = "Gene transfer for the treatment of erectile dysfunction has completed phase 1 safety testing and has shown the necessary safety to proceed to the next level of clinical trial. This review focuses on the background of the components of that have led to US Food and Drug Administration acceptance of human gene transfer trials for nonlethal disease.",
keywords = "Corpora cavernous, Erectile dysfunction, Gene transfer, Naked DNA, Overactive bladder, Phase I trial, Plasmid, Smooth muscle",
author = "Arnold Melman and Kelvin Davies",
year = "2010",
month = "11",
doi = "10.1007/s11934-010-0145-1",
language = "English (US)",
volume = "11",
pages = "421--426",
journal = "Current Urology Reports",
issn = "1527-2737",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - Gene therapy for erectile dysfunction

T2 - What is the future?

AU - Melman, Arnold

AU - Davies, Kelvin

PY - 2010/11

Y1 - 2010/11

N2 - Gene transfer for the treatment of erectile dysfunction has completed phase 1 safety testing and has shown the necessary safety to proceed to the next level of clinical trial. This review focuses on the background of the components of that have led to US Food and Drug Administration acceptance of human gene transfer trials for nonlethal disease.

AB - Gene transfer for the treatment of erectile dysfunction has completed phase 1 safety testing and has shown the necessary safety to proceed to the next level of clinical trial. This review focuses on the background of the components of that have led to US Food and Drug Administration acceptance of human gene transfer trials for nonlethal disease.

KW - Corpora cavernous

KW - Erectile dysfunction

KW - Gene transfer

KW - Naked DNA, Overactive bladder

KW - Phase I trial

KW - Plasmid

KW - Smooth muscle

UR - http://www.scopus.com/inward/record.url?scp=77958085764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958085764&partnerID=8YFLogxK

U2 - 10.1007/s11934-010-0145-1

DO - 10.1007/s11934-010-0145-1

M3 - Article

VL - 11

SP - 421

EP - 426

JO - Current Urology Reports

JF - Current Urology Reports

SN - 1527-2737

IS - 6

ER -